Evidence map›Paper›PMID 24122720›Full record

ArticleCirculation research2014

MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts.

Daren Wang, Hui Zhang, Min Li, Maria G Frid, Amanda R Flockton, B Alexandre McKeon, Michael E Yeager, Mehdi A Fini, Nicholas W Morrell, Soni S Pullamsetti and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Circulation research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 213 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Vascular Remodeling: The Multicellular Mechanisms of Pulmonary Hypertension.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. PTBP1 as a potential regulator of disease.Molecular and cellular biochemistry · 2024
    Review
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Daren WangFrom the Department of Pediatrics (D.W., H.Z., M.L., M.G.F., A.R.F., B.A.K., M.E.Y., M.A.F.), Department of Medicine (T.A.M., C.C.S.), Department of Medicine and Pediatrics (K.R.S.), Department of Medicine (N.W.M.), Department of Lung Development and Remodeling (S.S.P., S.V., W.S.), Department of Medicine (H.Z.), University of Colorado Anschutz Medical Campus, Aurora, CO; University of Cambridge, Cambridge, United Kingdom (N.W.M.); Addenbrooke's & Papworth Hospitals, Cambridge, United Kingdom (N.W.M.); Max-Planck-Institute for Heart and Lung Research; University of Giessen and Marburg Lung Center, Bad Nauheim, Germany (S.S.P., S.V., W.S.); and Shengjing Hospital of China Medical University, Shenyang, China (H.Z.).
Hui Zhang
Min Li
Maria G Frid
Amanda R Flockton
B Alexandre McKeon
Michael E Yeager
Mehdi A Fini
Nicholas W Morrell
Soni S Pullamsetti
Sivareddy Velegala
Werner Seeger
Timothy A McKinsey
Carmen C Sucharov
Kurt R Stenmark
Max Planck Institute for Heart and Lung Research · DEUniversities of Giessen and Marburg Lung Center · DEPapworth Hospital · GBUniversity of Cambridge · GB

Funding

VRAC and Rho in pulmonary EC proliferationP01HL014985 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STENMARK, KURT R. · 1985 to 2019
$35.1M
Translational Pulmonary Vascular Biology ProgramT32HL007171 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Sonia Castro Flores, Tim Lahm · 1985 to 2026
$9.4M
Fibroblasts and Mononuclear Fibrogenic Cells Drive Right Ventricular Pulmonary ArR01HL114887 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BULL, TODD M, BUTTRICK, PETER N. · 2012 to 2016
$3.4M
Regulation of Cardiac Signaling by Class I Histone DeacetylasesR01HL116848 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI MCKINSEY, TIMOTHY · 2013 to 2021
$3.1M
British Heart Foundation RG/13/4/30107NHLBI NIH HHS 1R01 HL114887-01NHLBI NIH HHS 2 T32 HL07171-36NHLBI NIH HHS 5P01HL014985-39NHLBI NIH HHS P01 HL014985NHLBI NIH HHS R01 HL114887NHLBI NIH HHS R01 HL116848NHLBI NIH HHS T32 HL007171
6 · The paper itself

Abstract

rationalePulmonary hypertensive remodeling is characterized by excessive proliferation, migration, and proinflammatory activation of adventitial fibroblasts. In culture, fibroblasts maintain a similar activated phenotype. The mechanisms responsible for generation/maintenance of this phenotype remain unknown.

objectiveWe hypothesized that aberrant expression of microRNA-124 (miR-124) regulates this activated fibroblast phenotype and sought to determine the signaling pathways through which miR-124 exerts effects. METHODS AND

resultsWe detected significant decreases in miR-124 expression in fibroblasts isolated from calves and humans with severe pulmonary hypertension. Overexpression of miR-124 by mimic transfection significantly attenuated proliferation, migration, and monocyte chemotactic protein-1 expression of hypertensive fibroblasts, whereas anti-miR-124 treatment of control fibroblasts resulted in their increased proliferation, migration, and monocyte chemotactic protein-1 expression. Furthermore, the alternative splicing factor, polypyrimidine tract-binding protein 1, was shown to be a direct target of miR-124 and to be upregulated both in vivo and in vitro in bovine and human pulmonary hypertensive fibroblasts. The effects of miR-124 on fibroblast proliferation were mediated via direct binding to the 3' untranslated region of polypyrimidine tract-binding protein 1 and subsequent regulation of Notch1/phosphatase and tensin homolog/FOXO3/p21Cip1 and p27Kip1 signaling. We showed that miR-124 directly regulates monocyte chemotactic protein-1 expression in pulmonary hypertension/idiopathic pulmonary arterial hypertension fibroblasts. Furthermore, we demonstrated that miR-124 expression is suppressed by histone deacetylases and that treatment of hypertensive fibroblasts with histone deacetylase inhibitors increased miR-124 expression and decreased proliferation and monocyte chemotactic protein-1 production.

conclusionsStable decreases in miR-124 expression contribute to an epigenetically reprogrammed, highly proliferative, migratory, and inflammatory phenotype of hypertensive pulmonary adventitial fibroblasts. Thus, therapies directed at restoring miR-124 function, including histone deacetylase inhibitors, should be investigated.

Indexed as

Cell MovementCell Proliferation3' Untranslated RegionsAdultAnimalsCattleChemokine CCL2Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27Familial Primary Pulmonary HypertensionFemaleFibroblastsForkhead Transcription FactorsHistone DeacetylasesHumansHypertension, Pulmonary3' Untranslated RegionsChemokine CCL2Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27Forkhead Transcription FactorsHistone DeacetylasesMicroRNAsMIRN124 microRNA, humanMirn124 microRNA, mouseMIRN124 microRNA, ratPolypyrimidine Tract-Binding ProteinReceptor, Notch1anoxiahypertension, pulmonarymigrationneoplasmsproliferation

Identifiers

PMID24122720
PMCPMC4117588
OpenAlexW2155295345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.